1. Home
  2. AROC vs APLS Comparison

AROC vs APLS Comparison

Compare AROC & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Archrock Inc.

AROC

Archrock Inc.

HOLD

Current Price

$36.52

Market Cap

6.5B

Sector

Energy

ML Signal

HOLD

Logo Apellis Pharmaceuticals Inc.

APLS

Apellis Pharmaceuticals Inc.

HOLD

Current Price

$41.05

Market Cap

5.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AROC
APLS
Founded
1990
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
5.2B
IPO Year
2007
2015

Fundamental Metrics

Financial Performance
Metric
AROC
APLS
Price
$36.52
$41.05
Analyst Decision
Strong Buy
Hold
Analyst Count
6
21
Target Price
$40.00
$33.59
AVG Volume (30 Days)
1.6M
62.6M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
2.32%
N/A
EPS Growth
74.29
112.50
EPS
0.41
0.15
Revenue
$1,489,818,000.00
$1,003,782,000.00
Revenue This Year
$7.06
N/A
Revenue Next Year
$5.27
$18.19
P/E Ratio
$87.98
$273.60
Revenue Growth
28.70
28.46
52 Week Low
$21.17
$16.83
52 Week High
$40.12
$41.14

Technical Indicators

Market Signals
Indicator
AROC
APLS
Relative Strength Index (RSI) 54.34 84.57
Support Level $34.68 $19.29
Resistance Level $37.33 $41.14
Average True Range (ATR) 1.00 0.06
MACD 0.17 -0.65
Stochastic Oscillator 74.32 58.33

Price Performance

Historical Comparison
AROC
APLS

About AROC Archrock Inc.

Archrock Inc is an energy infrastructure company focused on midstream natural gas compression. It is a provider of natural gas compression services, based on total compression fleet horsepower, to customers across the United States and a supplier of aftermarket services to customers that own compression equipment. The company operates through two segments: contract operations and aftermarket services. The contract operations segment includes designing, sourcing, owning, installing, operating, servicing, repairing, and maintaining its owned fleet of natural gas compression equipment, and generates the maximum revenue. The aftermarket services segment provides operations, maintenance, overhaul, and reconfiguration services, and sales of parts and components.

About APLS Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).

Share on Social Networks: